1-Methyl-2-morpholinocyclohexan | 96835-74-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-Methyl-2-morpholinocyclohexan
• 英文别名: 4-(2-methyl-cyclohexyl)-morpholine；4-(2-Methylcyclohexyl)morpholine
• CAS: 96835-74-4
• 化学式: C₁₁H₂₁NO
• 分子量: 183.294
• InChiKey: HPWDSPXYVFNPTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-(2-甲基环己烯-1-基)吗啉 在 亚磷酸 作用下， 生成 1-Methyl-2-morpholinocyclohexan
  参考文献：
  名称：

  Chemistry of phosphorous acid: new routes to phosphonic acids and phosphate esters

  摘要：

  DOI：

  10.1021/jo00399a041

文献信息

• [EN] CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY<br/>[FR] PYRIDINES CONDENSEES ET PYRIMIDINES A ACTIVITE TIE2 (TEK)
  申请人：ASTRAZENECA AB

  公开号：WO2004013141A1

  公开（公告）日：2004-02-12

  A compound of the Formula (I), wherein A together with the carbon atoms to which it is attached forms a fused 5-membered heteroaryl ring, wherein said heteroaryl ring contains 1 or 2 heteroatoms selected from O, N and S, and wherein the 5-membered ring containing G is linked to the ring formed by A in the meta position to the bridgehead carbon marked # in Formula (I); G is selected from O, S and NR5; Z is selected from N and CR6; Q1 is selected from optionally substituted aryl and heteroaryl, and the substituents R1 to R6 are as defined in the text for use in the production of an anti-angiogenic effect in a warm blooded animal such as man.

  化合物的公式（I），其中A与其连接的碳原子一起形成一个融合的5-成员杂环芳烃环，其中所述的杂环芳烃环包含1个或2个从O、N和S中选择的杂原子，并且包含G的5-成员环与在公式（I）中标记为桥头碳#的A形成的环在间位连接；G从O、S和NR5中选择；Z从N和CR6中选择；Q1从可选择的取代芳基和杂环芳基中选择，取代基R1到R6如文本中所定义，用于在温血动物（如人）中产生抗血管生成作用。
• Condensed pyridines and pyrimidines with tie2 (tek) activity
  申请人：Luke Arthur Richard William

  公开号：US20050256140A1

  公开（公告）日：2005-11-17

  A compound of the Formula (I), wherein A together with the carbon atoms to which it is attached forms a fused 5-membered heteroaryl ring, wherein said heteroaryl ring contains 1 or 2 heteroatoms selected from O, N and S, and wherein the 5-membered ring containing G is linked to the ring formed by A in the meta position to the bridgehead carbon marked # in Formula (I): G is selected from O, S and NR 5 ; Z is selected from N and CR 6 ; Q 1 is selected from optionally substituted aryl and heteroaryl, and the substituents R 1 to R 6 are as defined in the text for use in the production of an anti-angiogenic effect in a warm blooded animal such as man.

  化合物的式子（I），其中A与其连接的碳原子一起形成一个融合的5元杂环芳基环，其中该杂环芳基环含有1或2个从O，N和S中选择的杂原子，并且含有G的5元环与在式子（I）中被标记为#的桥头碳上的A形成的环在间位连接：G从O，S和NR5中选择；Z从N和CR6中选择；Q1从可选取代的芳基和杂环基中选择，取代基R1到R6如文本中所定义，用于在温血动物如人中产生抗血管生成效应的制备。
• CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY
  申请人：Astrazeneca AB

  公开号：EP1537112A1

  公开（公告）日：2005-06-08
• US7427616B2
  申请人：——

  公开号：US7427616B2

  公开（公告）日：2008-09-23
• US7507545B2
  申请人：——

  公开号：US7507545B2

  公开（公告）日：2009-03-24